EGFR and cancer: Given EGF would activate the PI3K/Akt/mTOR signaling pathway [27], it is crucial to investigate whether or not MeCDDA can alter the expression level of EGFR on SCLC cells or induce conformational changes in EGF protein structure, achieving its anti-cancer effect.